PTK2 and cancer: Studies of in vitro and in vivo cancer models have shown an enhanced anti-tumoural effect of FAK inhibition when delivered in combination with cytotoxic drugs or agents that targeted angiogenesis, such as the receptor tyrosine kinase inhibitors.